My research interests include developing novel therapeutics for treatment of genitourinary malignancies. My translational research has been focused on testing small-molecule inhibitors targeting the Jak2/Stat5a/b signaling pathway in prostate cancer using ex-vivo preclinical model systems like human prostate cancer organ cultures.
Our laboratory has shown that active Stat5a/b is critical for prostate cancer cell survival and growth and that the Jak2/Stat5a/b signaling pathway in prostate cancer plays a role in the progression of organ-confined prostate cancer to castration-resistant and/or disseminated disease. The Jak2/Stat5a/b pathway provides various molecular targets for developing rational targeted therapeutics for prostate cancer and we have tested small-molecule inhibitors including Jak2 inhibitor and Stat5 inhibitor targeting this pathway with promising results.
I am interested in developing early phase clinical trials using novel targeted agents for genitourinary cancers with an emphasis on prostate and bladder cancer.